Woodline Partners’s Maravai LifeSciences MRVI Stock Holding History

Woodline Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,517	Closed	-$1.08M	–	854
2022 Q1	$1.08M	Sell	30,517 -300,946	-91%	-$10.1M	0.02%	463
2021 Q4	$13.9M	Sell	331,463 -60,898	-16%	-$2.47M	0.2%	144
2021 Q3	$19.3M	Sell	392,361 -60,583	-13%	-$2.96M	0.31%	91
2021 Q2	$18.9M	Sell	452,944 -61,013	-12%	-$2.36M	0.35%	73
2021 Q1	$18.3M	Sell	513,957 -105,260	-17%	-$3.49M	0.41%	72
2020 Q4	$17.4M	Buy	+619,217	New	+$17.2M	0.46%	68

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Woodline Partners's MRVI Position: Q2 2022 in Review

Woodline Partners sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 30,517 shares — an estimated $1.08M sold.

Woodline Partners first reported a position in MRVI in Q4 2020 and held it in 6 quarters. The position peaked at $19.3M in Q3 2021. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

Woodline Partners reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
Woodline Partners sold 30,517 Maravai LifeSciences shares in Q2 2022, an estimated $1.08M.
Woodline Partners first reported a position in Maravai LifeSciences in Q4 2020 and held it in 6 quarters.
Woodline Partners's Maravai LifeSciences position peaked at $19.3M in Q3 2021.
216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Woodline Partners's 13F filing for Q2 2022, filed 15 Aug 2022.